266 related articles for article (PubMed ID: 36174583)
1. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
[TBL] [Abstract][Full Text] [Related]
2. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
[TBL] [Abstract][Full Text] [Related]
3. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
4. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Gingras G; Jit M; Boily MC; Bloem P; Brisson M
Lancet Public Health; 2023 Oct; 8(10):e788-e799. PubMed ID: 37777288
[TBL] [Abstract][Full Text] [Related]
5. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
6. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
7. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
8. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R
Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
[TBL] [Abstract][Full Text] [Related]
9. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.
Baisley K; Kemp TJ; Kreimer AR; Basu P; Changalucha J; Hildesheim A; Porras C; Whitworth H; Herrero R; Lacey CJ; Schiller JT; Lucas E; Mutani P; Dillner J; Indangasi J; Muwonge R; Hayes RJ; Pinto LA; Watson-Jones D
Lancet Glob Health; 2022 Oct; 10(10):e1485-e1493. PubMed ID: 36113532
[TBL] [Abstract][Full Text] [Related]
10. Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India.
M de Carvalho T; Man I; Georges D; Saraswati LR; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Sankaranarayanan R; Basu P; Berkhof J; Bogaards JA; Baussano I
BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37931940
[TBL] [Abstract][Full Text] [Related]
11. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
Diaz M; Kim JJ; Albero G; de Sanjosé S; Clifford G; Bosch FX; Goldie SJ
Br J Cancer; 2008 Jul; 99(2):230-8. PubMed ID: 18612311
[TBL] [Abstract][Full Text] [Related]
12. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
Prem K; Choi YH; Bénard É; Burger EA; Hadley L; Laprise JF; Regan MC; Drolet M; Sy S; Abbas K; Portnoy A; Kim JJ; Brisson M; Jit M
BMC Med; 2023 Aug; 21(1):313. PubMed ID: 37635227
[TBL] [Abstract][Full Text] [Related]
13. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
[TBL] [Abstract][Full Text] [Related]
14. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis.
Bonjour M; Charvat H; Franco EL; Piñeros M; Clifford GM; Bray F; Baussano I
Lancet Public Health; 2021 Jul; 6(7):e510-e521. PubMed ID: 33864738
[TBL] [Abstract][Full Text] [Related]
15. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
16. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
17. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study.
Abbas KM; van Zandvoort K; Brisson M; Jit M
Lancet Glob Health; 2020 Apr; 8(4):e536-e544. PubMed ID: 32105613
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
[TBL] [Abstract][Full Text] [Related]
19. Estimating the effect of HIV on cervical cancer elimination in South Africa: Comparative modelling of the impact of vaccination and screening.
Boily MC; Barnabas RV; Rönn MM; Bayer CJ; van Schalkwyk C; Soni N; Rao DW; Staadegaard L; Liu G; Silhol R; Brisson M; Johnson LF; Bloem P; Gottlieb S; Broutet N; Dalal S
EClinicalMedicine; 2022 Dec; 54():101754. PubMed ID: 36583170
[TBL] [Abstract][Full Text] [Related]
20. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
